
Aura Biosciences Investor Relations Material
Latest events

Status Update
Aura Biosciences

Corporate Presentation
16 May, 2025

Q1 2025
15 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aura Biosciences Inc
Access all reports
Aura Biosciences Inc. is a biotechnology company focused on developing therapies for cancer treatment. It specializes in the creation of virus-like drug conjugates (VDC) technology, aiming to address tumors with significant unmet medical needs in ocular and urologic oncology. A key development in their portfolio is AU-011, a VDC candidate targeting primary choroidal melanoma. The company also explores the potential of AU-011 for other ocular oncology indications, including choroidal metastases, and is conducting Phase 2 dose-escalation trials. Aura Biosciences is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Aura Biosciences Inc


Corporate Presentation
Aura Biosciences Inc


Corporate Presentation
Aura Biosciences Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AURA
Country
🇺🇸 United States